Heterozygous Eif4nif1 Stop-Gain Mice Replicate the Primary Ovarian Insufficiency Phenotype in Women
Endocrinology · 2025
DOI: 10.1210/endocr/bqaf014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology, 2025. Verfasst von Mika Moriwaki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Metabolism and Diabetes, University of Utah School of Medicine, Salt Lake City, UT 84112, USA. Hauptthemen laut MEDLINE: Primary Ovarian Insufficiency. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Center for Research in Reproduction Ligand Assay and Analysis Core, NIH HHS, NICHD.
Abstract (Originalsprache)
We created the c.1286C>G stop-gain mutation found in a family with primary ovarian insufficiency (POI) at age 30 years. The Eif4enif1 C57/Bl6 transgenic mouse model contained a floxed exon 10-19 cassette with a conditional knock-in cassette containing the c.1286C>G stop-gain mutation in exon 10. The hybrid offspring of CMV-Cre mice with Eif4enif1WT/flx mice were designated Eif4enif1WT/Δ for simplicity. A subset of female heterozygotes (Eif4enif1WT/Δ) had no litters. In those with litters, the final litter was earlier (5.4 ± 2.6 vs 10.5 ± 0.7 months; P = .02). Heterozygous breeding pair (Eif4enif1WT/Δ × Eif4enif1WT/Δ) litter size was 60% of WT litter size (3.9 ± 2.0 vs 6.5 ± 3.0 pups/litter; P < .001). The genotypes were 35% Eif4enif1WT/flx and 65% Eif4enif1WT/Δ, with no homozygotes. Homozygote embryos did not develop beyond the 4- to 8-cell stage. The number of follicles in ovaries from Eif4enif1WT/Δ mice was lower starting at the primordial (499 ± 290 vs 1445 ± 381) and primary follicle stage (1069 ± 346 vs 1450 ± 193) on day 10 (P < .05). The preantral follicle number was lower starting on day 21 (213 ± 86 vs 522 ± 227; P < .01). Examination of ribosome protected mRNAs demonstrated altered mRNA expression. The Eif4enif1 stop-gain mice replicate the POI phenotype in women based on an earlier end to reproduction due to oocyte loss. The unique mouse model provides a platform to study regulation of protein translation across oocyte and embryo development in mammals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Endocrinology, Metabolism and Diabetes, University of Utah School of Medicine, Salt Lake City, UT 84112, USA.
- Department of Cell Biology & Physiology, University of New Mexico Health Sciences Center, Albuquerque, NM 87106, USA.
- Andrology and IVF Laboratory, Department of Surgery (Urology), University of Utah School of Medicine, Salt Lake City, UT 84108, USA.
- Program in Molecular Medicine, University of Utah, Salt Lake City, UT 84112, USA.
- Biomedical Informatics Core of the Clinical and Translational Science Institute, University of Utah, Salt Lake City, UT 84112, USA.
- Department of Internal Medicine, University of Utah, Salt Lake City, UT 84132, USA.
ORCID-Profile: Corrine K Welt
Förderung
- Center for Research in Reproduction Ligand Assay and Analysis Core
- NIH HHS
- NICHD
- NICHD NIH HHS
- R01HD100447
- The University of Virginia
Zitieren
APA
Moriwaki, M., Liu, L., James, E. R., Tolley, N. D., O'Connor, A. M., Emery, B., Aston, K. I., Campbell, R. A., & Welt, C. K. (2025). Heterozygous Eif4nif1 Stop-Gain Mice Replicate the Primary Ovarian Insufficiency Phenotype in Women. Endocrinology. https://doi.org/10.1210/endocr/bqaf014
Vancouver
Moriwaki M, Liu L, James ER, Tolley ND, O'Connor AM, Emery B, et al. Heterozygous Eif4nif1 Stop-Gain Mice Replicate the Primary Ovarian Insufficiency Phenotype in Women. Endocrinology. 2025. doi:10.1210/endocr/bqaf014
BibTeX
@article{Moriwaki2025,
author = {Moriwaki, Mika and Liu, Lihua and James, Emma R and Tolley, Neal D and O'Connor, Ashley M and Emery, Benjamin and Aston, Kenneth Ivan and Campbell, Robert A and Welt, Corrine K},
title = {Heterozygous Eif4nif1 Stop-Gain Mice Replicate the Primary Ovarian Insufficiency Phenotype in Women},
journal = {Endocrinology},
year = {2025},
doi = {10.1210/endocr/bqaf014}
}
EUVIMED